Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more

M. Cea, A. Cagnetta, A. Garuti, G. Cirmena, I. Rocco, E. Moran, V. Grillo, A. Ballestrero, F. Patrone, A. Nencioni

Research output: Contribution to journalArticlepeer-review

Abstract

The current treatment of chronic myelogenous leukemia (CML) is one of the most successful examples of molecularly targeted therapy in cancer. The identification of the fusion oncogene BCR-ABL allowed the discovery of small molecule inhibitors of its tyrosine kinase activity which, in turn, have literally revolutionized the treatment of this disease. However, large part of a successful clinical management of CML relies on appropriate diagnosis, molecular monitoring and identification of mutations potentially leading to drug resistance. These issues are discussed here together with an overview on how patients treated with tyrosine kinase inhibitors should be monitored.

Original languageEnglish
Pages (from-to)565-573
Number of pages9
JournalJournal of B.U.ON.
Volume14
Issue number4
Publication statusPublished - Oct 2009

Keywords

  • Chronic myelogenous leukemia
  • Cytogenetic analysis
  • Imatinib
  • Molecular monitoring
  • Mutational analysis
  • Resistance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research
  • Hematology
  • Radiology Nuclear Medicine and imaging

Fingerprint Dive into the research topics of 'Molecular diagnosis and monitoring of chronic myelogenous leukemia: BCR-Abl and more'. Together they form a unique fingerprint.

Cite this